Study of dornase alfa for severe stroke
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial is testing whether giving an anti-inflammatory drug called dornase alfa through a vein can reduce brain swelling and improve recovery after a severe stroke. The drug may help break up a component of inflammation that appears after stroke, potentially limiting further brain damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your stroke symptoms must have started within the last 12 hours before receiving the study drug.
- Your stroke must be considered severe (a score of 10 or more on the NIHSS – your doctor can confirm).
- You must not have had a stroke or heart attack in the previous month.
- You must not weigh more than 100 kg (about 220 pounds).
- You must not have severe kidney disease (GFR below 29) or be on dialysis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether giving a clot-busting medicine (IV thrombolysis) is safe and effective for people who have had a stroke and also recently took a direct oral anticoagulant (DOAC). If you've taken a DOAC in the last 48 hours, this trial may help doctors decide the best treatment for you.
This trial tests whether giving a clot-dissolving medicine (alteplase or tenecteplase) is safe and effective for people who have had a stroke and are taking a blood thinner (DOAC) like apixaban or rivaroxaban. It aims to see if this treatment can still be given within a few hours of the stroke.
This study looks at how certain proteins in the blood change after a procedure to remove a large blockage in a brain artery. The goal is to better understand recovery after stroke treatment.
This trial tests whether filtering inflammatory substances from the blood using a special device can improve recovery in people with severe ischemic stroke. You must be within 48 hours of stroke onset and have significant disability or large areas of brain injury.
This trial tests whether giving a clot-busting drug remotely (via video link with a specialist) can help people having an acute stroke. It aims to see if this approach can improve recovery and outcomes for stroke patients in Oman.
This study looks at how your immune system reacts to stroke treatments like clot-busting drugs or mechanical clot removal. The goal is to see if immune markers can predict recovery, which could help tailor future stroke care.
Hear when a new Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.